Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2009
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing vaccines using its proprietary Virus-Like Particle (VLP) platform. Key product candidates include vaccines for H5N1 avian influenza, H1N1 pandemic influenza, seasonal influenza, Varicella Zoster (Shingles), and Respiratory Syncytial Virus (RSV). The company operates a GMP pilot manufacturing facility in Rockville, Maryland.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
|---|---|---|
| Revenues | $50 | $800 |
| Net Loss | $(16,889) | $(17,127) |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.28) |
| Cash and Cash Equivalents (End of Period) | $25,216 | $23,513 |
| Short-Term Investments (Fair Value) | $5,978 | $6,962 |
| Total Debt (Convertible Notes + Notes Payable) | $5,684 | $22,908 |
| Working Capital | $21,849 | $7,379 |
Note: Debt figures reflect balances as of June 30, 2009. Convertible notes were repaid in July 2009.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 94% to $50,000 for the six months ended June 30, 2009, compared to $800,000 in the prior year. This was primarily due to the completion of a National Institutes of Health (NIH) contract in January 2009.
- Operating Expenses: Total operating costs decreased 7% to $15.0 million. Research and Development (R&D) expenses declined 3% to $9.6 million, and General and Administrative (G&A) expenses declined 15% to $5.5 million, driven by reduced employee-related costs and facility expenses.
- Discontinued Operations: The company recorded no loss from discontinued operations in 2009, compared to a $1.7 million loss in the same period in 2008, following the exit from its Philadelphia manufacturing facility in August 2008.
- Investment Impairment: The company recorded a $1.3 million other-than-temporary impairment charge on auction rate securities due to illiquidity in credit markets. This was partially offset by a $0.5 million recovery of previously recorded losses recognized in other comprehensive income.
- Debt Reduction: Significant debt reduction occurred via the early repayment of $17.0 million in convertible notes in April 2009 (partially via cash and partially via stock issuance). Remaining debt at quarter-end was $5.0 million in convertible notes and $0.7 million in other notes payable.
Guidance, Outlook, and Risks
Capital Resources and Liquidity: Management believes it has adequate capital to operate for at least the next twelve months based on cash on hand ($25.2 million), proceeds from a $3.0 million equity investment by ROVI Pharmaceuticals (closed July 6, 2009), and subsequent stock sales under an "At the Market" issuance agreement. However, the company plans to raise additional capital in 2009 to continue operations beyond that period and has not secured new financing commitments.
Strategic Developments:
- ROVI Partnership: Signed a letter of intent to license VLP technology to ROVI Pharmaceuticals for influenza vaccines in Spain and Portugal, with non-exclusive rights in Europe, Latin America, and Africa. A non-profit foundation is being formed to support Phase III clinical development.
- Cadila Joint Venture: Formed a joint venture (CPL Biologicals Limited) with Cadila Pharmaceuticals for the Indian market. Cadila committed $8 million over three years to support the JV.
- H1N1 Response: Began production of H1N1 VLP vaccine batches in June 2009, demonstrating a 12-week cycle time from strain identification to first batch.
Risks and Contingencies:
- Investment Liquidity: $6.0 million of short-term investments are held in auction rate securities that have failed to auction, creating liquidity risk. The company has recorded cumulative impairment charges of approximately $2.1 million.
- Related Party Notes: Two promissory notes from former directors totaling approximately $2.0 million are currently in default.
- Regulatory and Clinical Risk: No assurance that vaccine candidates will prove safe, effective, or receive regulatory approval. Commercial success depends on manufacturing scale-up and market acceptance.
- Foreign Operations: New collaborations in India and Spain expose the company to foreign regulatory, political, and economic risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $25.2 million cash balance plus subsequent financing proceeds to fund operations through 2010, given the lack of product revenue.
- Auction Rate Securities: Assess the recoverability of the $6.0 million in illiquid auction rate securities and the potential for further impairment charges.
- Debt Repayment: Confirm the full repayment of the $5.0 million convertible notes that matured in July 2009 and the impact of the stock issuance component on dilution.
- Related Party Defaults: Monitor the status of the $2.0 million in defaulted notes receivable from former directors and potential collection efforts.
- Collaboration Milestones: Track the finalization of definitive agreements with ROVI and Cadila, including funding commitments and regulatory timelines for Phase III trials.